However, retinal alterations after intravitreal anti-VEGF therapy for AMD are typically assessed in terms of visual acuity (VA) or central subretinal thickness (CST) in previous studies [12, 22], with little emphasis on changes in individual retinal layers or only a single layer such as retinal nerve fiber layer (NFL) or ganglion cell layer (GCL) [23, 24]. The gene discussed is VEGFA; the disease is age-related macular degeneration.